How did the COVID-19 pandemic change patient experience during radiation therapy for head and neck cancer: A single centre survey.

COVID-19 Head and neck Patient experience Radiotherapy

Journal

Journal of medical imaging and radiation sciences
ISSN: 1876-7982
Titre abrégé: J Med Imaging Radiat Sci
Pays: United States
ID NLM: 101469694

Informations de publication

Date de publication:
10 Aug 2024
Historique:
received: 25 05 2023
revised: 07 06 2024
accepted: 18 06 2024
medline: 12 8 2024
pubmed: 12 8 2024
entrez: 11 8 2024
Statut: aheadofprint

Résumé

Patients receiving treatment for head and neck cancer (HNC) with curative intent, will potentially undergo primary or adjuvant radiation therapy (RT). These patients require supportive management from an extended multi-disciplinary team, to manage the severe toxicities and distress that a course of treatment can bring. A survey was designed to determine if there were changes in the experience of HNC patients attending for radical RT, from the beginning to the end of their treatment course. During the conduct of the survey the COVID-19 pandemic began. As a result cancer services were adapted to keep patients receiving treatment protected from the virus, while continuing to treat their malignant disease. This enabled a comparison of HNC patient experiences pre-pandemic (PP) and during the pandemic (DP). The study aimed to assess the impact of changes in treatment logistics, implemented as a result of the COVID-19 pandemic, on the patient experience, analysing and comparing how well patients understood the information provided to them, their level of distress and anxiety during treatment, and their overall satisfaction with the experience. Eligible patients were receiving radical RT for HNC of any sub-site or histological type. Identical, anonymous surveys were distributed to patients at week 1 and the final week of RT. The initial PP questionnaire (distributed December 2019 to 11 One hundred and eighty two surveys were returned; 95 (52%) PP and 87 (48%) DP. Patients were moderately distressed from wearing the immobilisation mask towards the end of treatment DP with a statistically significant difference in the final week, median (IQR) values of 1 (0-4) PP and 2 (1-6) DP, p=0.024. Patients reported increased distress by attending daily for treatment by the final week of RT DP, with a PP and DP median of 1 (0-3) and 2 (1-4) respectively, p=0.039. Patients reporting increased levels of distress about attending for RT also reported high levels of anxiety about COVID-19 (r=0.40, p=0.005). COVID-19 anxiety score displayed a weak inverse association with overall treatment satisfaction score (r=-0.28, p=0.008). Despite the adapted COVID-19 working practices implemented and the challenges a course of head and neck RT entails, patients reported a positive experience attending for treatment, both PP and DP.

Sections du résumé

INTRODUCTION/BACKGROUND BACKGROUND
Patients receiving treatment for head and neck cancer (HNC) with curative intent, will potentially undergo primary or adjuvant radiation therapy (RT). These patients require supportive management from an extended multi-disciplinary team, to manage the severe toxicities and distress that a course of treatment can bring. A survey was designed to determine if there were changes in the experience of HNC patients attending for radical RT, from the beginning to the end of their treatment course. During the conduct of the survey the COVID-19 pandemic began. As a result cancer services were adapted to keep patients receiving treatment protected from the virus, while continuing to treat their malignant disease. This enabled a comparison of HNC patient experiences pre-pandemic (PP) and during the pandemic (DP). The study aimed to assess the impact of changes in treatment logistics, implemented as a result of the COVID-19 pandemic, on the patient experience, analysing and comparing how well patients understood the information provided to them, their level of distress and anxiety during treatment, and their overall satisfaction with the experience.
METHODS METHODS
Eligible patients were receiving radical RT for HNC of any sub-site or histological type. Identical, anonymous surveys were distributed to patients at week 1 and the final week of RT. The initial PP questionnaire (distributed December 2019 to 11
RESULTS RESULTS
One hundred and eighty two surveys were returned; 95 (52%) PP and 87 (48%) DP. Patients were moderately distressed from wearing the immobilisation mask towards the end of treatment DP with a statistically significant difference in the final week, median (IQR) values of 1 (0-4) PP and 2 (1-6) DP, p=0.024. Patients reported increased distress by attending daily for treatment by the final week of RT DP, with a PP and DP median of 1 (0-3) and 2 (1-4) respectively, p=0.039. Patients reporting increased levels of distress about attending for RT also reported high levels of anxiety about COVID-19 (r=0.40, p=0.005). COVID-19 anxiety score displayed a weak inverse association with overall treatment satisfaction score (r=-0.28, p=0.008).
CONCLUSION CONCLUSIONS
Despite the adapted COVID-19 working practices implemented and the challenges a course of head and neck RT entails, patients reported a positive experience attending for treatment, both PP and DP.

Identifiants

pubmed: 39128320
pii: S1939-8654(24)00443-0
doi: 10.1016/j.jmir.2024.101712
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101712

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Lisa Hay (L)

Department of Clinical Oncology, Beatson West of Scotland Cancer Centre, Glasgow G12 0YN, Scotland. Electronic address: Lisa.Hay@ggc.scot.nhs.uk.

Philip McLoone (P)

School of Health & Wellbeing, Clarice Pears Building, University of Glasgow, G12 8TB Scotland.

Frances Campbell (F)

Department of Clinical Oncology, Beatson West of Scotland Cancer Centre, Glasgow G12 0YN, Scotland.

Heather Reid (H)

Department of Clinical Oncology, Beatson West of Scotland Cancer Centre, Glasgow G12 0YN, Scotland.

Allan James (A)

Department of Clinical Oncology, Beatson West of Scotland Cancer Centre, Glasgow G12 0YN, Scotland.

Carolynn Lamb (C)

Department of Clinical Oncology, Beatson West of Scotland Cancer Centre, Glasgow G12 0YN, Scotland.

Stefano Schipani (S)

Department of Clinical Oncology, Beatson West of Scotland Cancer Centre, Glasgow G12 0YN, Scotland.

Derek Grose (D)

Department of Clinical Oncology, Beatson West of Scotland Cancer Centre, Glasgow G12 0YN, Scotland.

Christina Wilson (C)

Department of Clinical Oncology, Beatson West of Scotland Cancer Centre, Glasgow G12 0YN, Scotland.

Claire Paterson (C)

Department of Clinical Oncology, Beatson West of Scotland Cancer Centre, Glasgow G12 0YN, Scotland.

Classifications MeSH